<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
  <meta name="title" content="EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in â€¦"/>
  <meta name="description" content="AstraZenecas antibody combination for the prevention of Covid-19 retains neutralization activity against the SARS-CoV-2 variant, according to new data from two UK and US studies. A new study suggests that a new batch of antibodies could be used to prevent the disease."/><meta name="robots" content="index,follow"/><link rel="canonical" href="https://datosabiertos.com/open_data/2021-12-23/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities/">
  <link rel="icon" href="/img/favicon.ico"/>

  <title>EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities - Open Data</title>

  <link rel="preload" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
  <noscript><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css" integrity="sha384-xOolHFLEh07PJGoPkLv1IbcEPTNtaed2xpHsD9ESMhqIYd0nLMwNLD69Npy4HI+N" crossorigin="anonymous"></noscript>

  
  <link rel="stylesheet" href="/css/custom.css">
</head>

<body>
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MXMNS5J"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
  <main role="main" class="container">
    
    <header class="site-header py-3">
      <div class="row flex-nowrap justify-content-between align-items-center">
        <div class="col pt-1">
          <a class="site-header-name" href="/">
            <h1 class="site-header-name">Open Data</h1>
          </a>
        </div>
      </div>
    </header>
    

    
    <div class="container nav-bar">
      <div class="row nav">
        <a class="col-md-auto p-2" href="/es/">ES</a>
        <a class="col-md-auto p-2" href="/">EN</a>
      </div>
    </div>
    

    <div class="row">

      
      <div class="col">
        
<div class="content is-medium">
  <p class="article_item">
    <a href="https://www.businesswire.com/news/home/20211223005099/en/EVUSHELD-long-acting-antibody-combination-retains-neutralizing-activity-against-Omicron-variant-in-studies-from-Oxford-and-Washington-Universities" target="_new">EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities</a>
    <p>AstraZenecas antibody combination for the prevention of Covid-19 retains neutralization activity against the SARS-CoV-2 variant, according to new data from two UK and US studies. A new study suggests that a new batch of antibodies could be used to prevent the disease.</p>
    <b style="font-weight: bold;">Source: <i>businesswire.com</i></b>
    <br/>Published on <a href="/open_data/2021-12-23/">2021-12-23</a>
  </p>
</div>

    <div class="content is-medium">
        <h3>Related news</h3>
        <ul>
        
            <li><a href="/open_data/2021-12-25/2021-12-25--evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities">EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities</a></li>
        
            <li><a href="/open_data/2021-10-11/investegate-astrazeneca-plc-announcements-astrazeneca-plc-azd7442-phiii-trial-positive-in-covid-outpatients">Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC : AZD7442 PhIII trial positive in COVID outpatients</a></li>
        
            <li><a href="/open_data/2021-10-11/azd7442-reduced-risk-of-developing-severe-covid-19-or-death-in-tackle-phase-iii-outpatient-treatment-trial">AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial</a></li>
        
            <li><a href="/open_data/2021-10-12/astrazeneca-plc-via-public-azd7442-reduced-risk-of-developing-severe-covid-19-or-death-in-tackle-phase-iii-outpatient-treatment-trial">AstraZeneca plc ( via Public ) / AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial</a></li>
        
            <li><a href="/open_data/2021-11-18/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention">New Analyses of Two AZD7442 COVID - 19 Phase III Trials in High - Risk Populations Confirm Robust Efficacy and Long - Term Prevention</a></li>
        
            <li><a href="/open_data/2021-12-21/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study">Evusheld long - acting antibody combination retains neutralising activity against Omicron variant in independent FDA study</a></li>
        
            <li><a href="/open_data/2022-02-14/2022-02-14--astrazeneca-to-supply-the-us-government-with-an-additional-one-million-doses-of-evusheld-long-acting-antibody-combination-for-the-prevention-of-covid-">AstraZeneca to supply the US government with an additional one million doses of EVUSHELD long - acting antibody combination for the prevention of COVID - 19</a></li>
        
            <li><a href="/open_data/2022-09-12/2022-09-12--continued-attendance-in-a-prep-program-despite-low-adherence-and-non-protective-drug-levels-among-adolescent-girls-and-young-women-in-kenya-results-fr">Continued attendance in a PrEP program despite low adherence and non - protective drug levels among adolescent girls and young women in Kenya : Results from a prospective cohort study</a></li>
        
            <li><a href="/open_data/2021-11-04/tools-schema-root-news">tools , Schema - Root news</a></li>
        
        </ul>
    </div>
<div class="row">
  <div class="col-md-6">
    
      <a href="/open_data/2021-12-23/first-homes-gov-uk/">&laquo;&nbsp;First Homes - GOV . UK</a>
    
  </div>
  <div class="col-md-6 text-right">
    
      <a href="/open_data/2021-12-23/council-passes-koo-algorithm-bill-queenswide/">Council passes Koo algorithm bill | Queenswide &nbsp;&raquo;</a>
    
  </div>
</div>

    </div>
  </main>

  <footer class="site-footer">

    <div class="row">
      <div class="col-md-3"></div>
      <div class="col-md-3 col-md-center">

      </div>
      <div class="col-md-3 col-md-center">

      </div>
    </div>
  </div>
  </footer>

  
  

  
  
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
            new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
            j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
            '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
            })(window,document,'script','dataLayer','GTM-MXMNS5J');
        </script>
    

  
  <script src="https://cdn.jsdelivr.net/npm/jquery@3.5.1/dist/jquery.slim.min.js" integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj" crossorigin="anonymous"></script>
<script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-Fy6S3B9q64WdZWQUiU+q4/2Lc9npb8tCaSX9FK7E8HnRr0Jz8D6OP9dO5Vg3Q9ct" crossorigin="anonymous"></script>

</body>

</html>
